0000899243-20-017885.txt : 20200630 0000899243-20-017885.hdr.sgml : 20200630 20200630064741 ACCESSION NUMBER: 0000899243-20-017885 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200625 FILED AS OF DATE: 20200630 DATE AS OF CHANGE: 20200630 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: O'Leary James J CENTRAL INDEX KEY: 0001449753 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39344 FILM NUMBER: 201000383 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02452 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fusion Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001805890 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 270 LONGWOOD ROAD SOUTH CITY: HAMILTON STATE: A6 ZIP: L8P 0A6 BUSINESS PHONE: 289-799-0891 MAIL ADDRESS: STREET 1: 270 LONGWOOD ROAD SOUTH CITY: HAMILTON STATE: A6 ZIP: L8P 0A6 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-25 0 0001805890 Fusion Pharmaceuticals Inc. FUSN 0001449753 O'Leary James J C/O FUSION PHARMACEUTICALS INC. 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 ONTARIO, CANADA 0 1 0 0 Chief Medical Officer Stock Option (Right to Buy) 4.44 2020-03-16 4 A 0 351921 0.00 A 2030-03-16 Non-Voting Common Shares 351921 351921 D Stock Option (Right to Buy) 17.00 2020-06-25 4 A 0 26971 0.00 A 2030-06-18 Common Shares 26971 26971 D Stock Option (Right to Buy) 17.00 2020-06-25 4 A 0 60852 0.00 A 2030-06-25 Common Shares 60852 60852 D 25% of the shares subject to this option shall vest and become exercisable on March 16, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter. Prior to closing of the Issuer's initial public offering, such Non-Voting Common Shares will convert into Voting Common Shares and subsequently into Common Shares on a one-for-one basis. 25% of the shares subject to this option shall vest and become exercisable on June 18, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter. 25% of the shares subject to this option shall vest and become exercisable on June 25, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter. /s/ John Crowley, Attorney-in-Fact 2020-06-29